N
Navigator Medicines
Navigator Medicines leads the advancement of biologics for targeted immune regulation & restoration
About Navigator Medicines
Navigator Medicines is a clinical-stage biopharmaceutical company focused on developing targeted biologics for immune regulation and restoration. Launched in 2024 as a subsidiary of Sera Medicines, the Scotch Plains, New Jersey-based firm is channeling its resources toward creating new treatments for patients with complex and heterogeneous autoimmune diseases. The company's establishment was marked by a significant milestone in August 2024, when it secured $100 million in a Series A financing round co-led by prominent venture capital firms RA Capital Management and Forbion. This funding is primarily dedicated to advancing its lead asset, NAV-240.
The company's core strategy revolves around in-licensing and developing promising antibody therapeutics. In June 2024, Navigator licensed its lead candidate, NAV-240 (formerly IMB-101), from the South Korean biotech IMBiologics. The agreement gives Navigator rights to the asset outside of Asia (but including Japan) for an upfront payment of $20 million, with potential for future milestone payments. This strategic move positions Navigator to address a substantial market, with the global immunology market projected to grow significantly. The company's business model is centered on the clinical development and potential commercialization of its licensed assets, targeting unmet medical needs in the autoimmune sector. Key figures in the company's leadership include CEO and President Tausif 'Tosh' Butt, who was formerly president at Idorsia, and Chief Medical Officer Dr. Dana McClintock, who brings experience from Genentech.
Navigator's lead product, NAV-240, is a clinical-stage bispecific antibody that simultaneously targets two validated pathways in inflammatory diseases: OX40L and TNFα. This dual-targeting mechanism is designed to modulate both the adaptive and innate immune responses, potentially offering superior efficacy compared to therapies that target only one pathway. By blocking both OX40L and TNFα, NAV-240 aims to provide a more effective treatment option for complex conditions like rheumatoid arthritis, including for patients who do not respond to existing anti-TNF agents. The company's pipeline also includes NAV-242, a next-generation version of the anti-OX40L/TNFα antibody with an extended half-life, and other preclinical assets targeting the OX40L pathway. The first participants in a Phase 1b trial for NAV-240 were dosed in May 2025, a key step toward planned patient studies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 27
- Open positions
- 5
- Dealroom signal
- 27.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Healthcare Services, Biotechnology, Medical & Healthcare, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2024 | $100M | $400M | RA Capital Management · Forbion Capital Partners | ↗ |
Growth signals
Latest recorded traffic for Navigator Medicines is 1.6K monthly website visits, down 44.8% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Navigator Medicines in the San Mateo ecosystem
The Navigator Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
RA Capital Management
Forbion Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Navigator Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Navigator Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









